A perspective on arterionephrosclerosis: From pathology to potential pathogenesis

Journal of Nephrology

Volumn 20, Issue 5, 2007, Pages 518-524

  Marcantoni, Carmelita ^a   Fogo, Agnes B ^b  

^a CANNIZZARO HOSPITAL   (Italy)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Arteriosclerosis; Glomerulosclerosis; Hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE;

AFRICAN AMERICAN; ARTICLE; AUTOREGULATION; CAUCASIAN; CELL COUNT; COMORBIDITY; DEATH; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; ETHNICITY; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULOSCLEROSIS; HEREDITY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FIBROSIS; LOW BIRTH WEIGHT; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; MORPHOLOGY; NEPHRON; NEPHROSCLEROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEINURIA; RACE DIFFERENCE; THROMBOSIS; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; HOMEOSTASIS; NEWBORN; PATHOLOGY; REVIEW; RISK FACTOR;

GENETIC PREDISPOSITION TO DISEASE; HOMEOSTASIS; HUMANS; HYPERTENSION; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; METABOLIC SYNDROME X; NEPHRONS; NEPHROSCLEROSIS; RISK FACTORS; THROMBOSIS;

EID: 38349038378     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. ERA-EDTA Registry. ERA-EDTA registry 2003 annual report. Amsterdam (Netherlands): Academic Medical Centre 2005.
2. US Renal Data System. USRDS 2004 annual data report: atlas of end stage renal disease in the United States. Bethesda MD (USA): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2004.
3. Zarif L, Covic A, Iyengar S, Sehgal AR, Sedor JR, Schelling JR. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant 2000; 15: 1801-7.
4. Perneger TV, Whelton PK, Klag MJ, Rossiter KD. Diagnosis of hypertensive end stage renal disease: effect of patients' race. Am J Epidemiol 1995; 141: 10-5.
5. Schlessinger SD, Tankersley M, Curtis J. Clinical documentation of end-stage renal disease due to hypertension. Am J Kidney Dis 1994; 5: 655-60.
6. Zucchelli P, Zuccala A. Recent data on hypertension and progressive renal disease. J Hum Hypertens 1996; 10: 679-82.
7. Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA, Glassock R; the AASK Pilot Study Investigators. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study on Kidney Disease (AASK) trial. Kidney Int 1997; 51: 244-52.
8. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA; for the Hypertension Detection and Follow-up Program Cooperative Group. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the hypertension detection and follow-up program. Hypertension 1989; 13 (5 Suppl): 180-93.
9. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA 1997; 277: 1293-8.
10. Siewert-Delle A, Ljungman S, Andersson OK, Wilhelmsen L. Does treated primary hypertension lead to end-stage renal disease? A 20-year follow up of the Primary Prevention Study in Goteborg, Sweden. Nephrol Dial Transplant 1998; 13: 3084-90.
11. Hsu CY. Does non-malignant hypertension cause renal insufficiency? Evidence-based perspective. Curr Opin Nephrol Hypertens 2002; 11: 267-72.
12. Dasgupta I, Porter C, Innes A, Burden R. Benign hypertensive nephrosclerosis. QJ Med 2007; 100: 113-9.
13. Vikse BE, Aasarod K, Bostad L, Iversen BM. Clinical prognostic factors in biopsy proven benign nephrosclerosis. Nephrol Dial Transplant 2003; 18: 517-23.
14. Takebayashi S, Kiyoshi Y, Hisano S, Uesugi N, Sasatomi Y, Meng J, Sakata N. Benign nephrosclerosis: incidence, morphology and prognosis. Clin Nephrol 2001; 55: 349-56.
15. Wehrmann M, Bohle A. The longterm prognosis of benign nephrosclerosis accompanied by focal glomerulosclerosis and renal cortical interstitial fibrosis, designated so called decompensated benign nephrosclerosis by Fahr, Bohle and Ratscheck. Pathol Res Pract 1998; 194: 571-6.
16. Raine AE. Hypertension and the kidney. Br Med Bull 1994; 50: 322-41.
17. Marcantoni C, Ma LJ, Federspiel C, Fogo AB. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int 2002; 62: 172-80.
18. McManus JFA, Lupton C. Ischemic obsolescence of renal glomeruli: the natural history of the lesions and their relation to hypertension. Lab Invest 1960; 9: 413.
19. Fahr T. Pathologische anatomie des Morbus Brightii. In Henke F, Lubarsch O Eds. Handbuch der Speziellen Pathologischen Anatomie und Histologie (Vol. 6, Part 1). Berlin (Germany): Springer 1925; 156.
20. Bohle A, Ratschek M. The compensated and decompensated form of benign nephrosclerosis. Pathol Res Pract 1982; 174: 357-67.
21. Hill GS, Heudes D, Jacquot C, Gauthier E, Bariety J. Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension. Kidney Int 2006; 69: 823-31.
22. Hill GS, Heudes D, Bariety J. Morphometrc study of arterioles and glomeruli in the aging kidney suggests focal loss of autoregulation. Kidney Int 2003; 63: 1027-36.
23. Kincaid-Smith P. Clinical diagnosis of hypertensive nephrosclerosis. Nephrol Dial Transplant 1999; 14: 2255-67.
24. Tracy RE. Renovesculopathies of hypertension and the rise of blood pressure with age in blacks and whites. Semin Nephrol 1996; 16: 126-33.
25. Tracy RE, Bandharu SY, Oalmann MC, Guzman MA, Newmann WP 3rd. Blood pressure and nephrosclerosis in black and whites men and women aged 25 to 54. Mod Pathol 1991; 4: 602-9.
26. Tracy RE, Berenson GS, Cueto-Garcia L, Wattigney WA, Barrett TJ. Nephrosclerosis and aortic atherosclerosis from age 6 to 70 years in the United States and Mexico. Virchows Arch A Pathol Anat Histopathol 1992; 420: 479-88.
27. Tracy RE, Rios-Dalenz JL. Rarity of hypertensive stigmata in aging renocortical arteries of Bolivians. Virchows Arch 1994; 424: 307-14.
28. Meyrier A, Simon P, Montseny JJ, Eladari D, Charasse C. Vascular nephropathies and nephroclerosis: epidemiology and pathophysiology. Adv Nephrol Necker Hosp 1997; 26: 207-45.
29. Goforth RL, Rennke H, Sethi S. Renal vascular sclerosis is associated with inherited thrombophilias. Kidney Int 2006; 70: 743-50.
30. Koupepidou P, Deltas C, Christofides TC, Athanasiou Y, Zouvani I, Pierides A. The MHTFR 677TT and 677CT/128AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure. Int Angiol 2005; 24: 287-94.
31. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012.
32. Fogo AB. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000; 35: 179-88.
33. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002;283:F209-20.
34. Marcantoni C, Ma LJ, Donnert E, Federspiel C, Fogo AB. Plasminogen activator inhibitor-1 (PAI-1) and peroxisome proliferator-activated receptor-g (PPARg) in hypertensive nephrosclerosis. J Am Soc Nephrol 2000; 11: 351A.
35. Fogo AB. The clot thickens. Kidney Int 2006; 70: 620-1.
36. Brenner BM, Chertow GM. Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis 1994; 23: 171-5.
37. Pesce C, Schmidt K, Fogo A, Okoye MI, Kim R, Striker LJ, Striker GE. Glomerular size and the incidence of renal disease in African Americans and Caucasians. J Nephrol 1994; 7: 355-8.
38. Fogo AB. Hypertensive risk factors in kidney disease in African Americans. Kidney Int 2003; 63: S17-21.
39. Keller G, Zummer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med 2003; 348: 101-8.
40. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest 1995; 95: 948-53.
41. Mallamaci F, Zuccalà A, Zoccali C, Testa A, Gaggi R, Spoto B, Martorano C, Curatola A, Misefari V, Cuzzola F, Romeo G, Zucchelli P. The deletion polymorphism of the angiotensin-converting enzyme is associated with nephroangiosclerosis. Am J Hypertens 2000; 13: 433-7.
42. Fernandez Llama P, Poch E, Oriola J, Botey A, Coll E, Darnell A, Rivera F, Revert L. Angiotensin-converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis. Kidney Int 1998; 53: 1743-7.
43. Kincaid-Smith P. Hypothesis: obesity and the insulin resistance syndrome play a major role in end stage renal failure attributed to hypertension and labeled "hypertensive nephrosclerosis". J Hypertens 2004; 22: 1051-5.
44. Kambham N, Markowitz GS, Valeri AM, Un J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-509.